A newly studied hormone is revealing an unexpected connection between metabolism and the brain. A hormone that can reverse ...
These foods are the heaviest hitters. While GLP-1 drugs have transformed how many people think about weight loss, the ...
5don MSN
Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.
Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the ...
Study of almost 28,000 people also identifies genetic variants that raise the risk of gastrointestinal side effects from ...
The Endocrine Society has concerns of possible delays in care and other problematic areas of The Lancet Commission’s proposed new obesity framework; a Commission author cites ‘conceptual confusions.’ ...
Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has ...
"ACC 2026: Ventyx’s VTX3232 Phase IIa results show anti-inflammatory benefits in obesity" was originally created and ...
The global rise in the prevalence of obesity highlights the need for accessible and effective solutions for obesity ...
With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...
MedPage Today on MSN
Proposed Obesity Criteria Could Delay Care, Top Society Warns
Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...
Among medically eligible respondents, nearly three-fourths (74%) identified GLP-1 coverage as a top-tier health priority. One ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results